# Immune Thrombocytopenic Purpura and Intracranial Stenting

## TL;DR

A high-risk ITP patient was successfully managed with DAPT after treatment with dexamethasone, showing it's possible to safely use antiplatelet drugs in such cases.

## Contribution

Demonstrates successful DAPT management in a high-risk ITP patient following ITP stabilization with dexamethasone.

## Key findings

- A 65-year-old ITP patient was safely treated with DAPT after ITP stabilization with dexamethasone.
- The patient did not require additional ITP treatment during the DAPT period.
- Successful neurosurgical stenting was achieved without immediate complications.

## Abstract

Patients with immune thrombocytopenic purpura (ITP) presenting with indications for dual antiplatelet therapy (DAPT) can be difficult to manage due to the precarious balance of managing the need for increased platelet counts as well as inhibition of platelet activity. This case represents a 65 year old woman with ITP who presented with a bilateral subarachnoid hemorrhage secondary to a left ophthalmic aneurysm that required placement of a pipeline embolization device (PED) necessitating DAPT. After treatment of her ITP with pulse dexamethasone for four days, she was safely discharged on one month of DAPT with aspirin and ticagrelor then switched to aspirin monotherapy without any immediate complications. During her period of DAPT, she did not receive additional medical treatment for her ITP. This case successfully presents a high-risk ITP patient requiring DAPT for a neurosurgical procedure and illustrates that these patients can be safely and successfully treated with DAPT once their ITP is stabilized.